Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies Victoria P. Werth, MD – University of Pennsylvania
3:10 PM – 3:20 PM ET
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus Victoria P. Werth, MD – University of Pennsylvania
3:20 PM – 3:30 PM ET
Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study Joan T. Merrill, MD – Oklahoma Medical Research Foundation
3:30 PM – 3:40 PM ET
Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis Richard Furie, MD – Northwell Health
3:40 PM – 3:50 PM ET
Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial Eliza F. Chakravarty, MD – Oklahoma Medical Research Foundation
